Daniel J. George
About
Daniel J. George is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology.
According to data from OpenAlex, Daniel J. George has authored 255 papers receiving a total of 8.0k indexed citations (citations by other indexed papers that have themselves been cited), including 193 papers in Pulmonary and Respiratory Medicine, 108 papers in Oncology and 74 papers in Molecular Biology. Recurrent topics in Daniel J. George's work include Prostate Cancer Treatment and Research (102 papers), Renal cell carcinoma treatment (88 papers) and Cancer Immunotherapy and Biomarkers (48 papers). Daniel J. George is often cited by papers focused on Prostate Cancer Treatment and Research (102 papers), Renal cell carcinoma treatment (88 papers) and Cancer Immunotherapy and Biomarkers (48 papers). Daniel J. George collaborates with scholars based in United States, Canada and United Kingdom. Daniel J. George's co-authors include Philip W. Kantoff, Susan Halabi, Eric J. Small, M. Dror Michaelson, Andrew J. Armstrong, Mario A. Eisenberger, William Oh, Michael J. Morris, Michael R. Harrison and Tian Zhang and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and Journal of Biological Chemistry.
In The Last Decade
Daniel J. George
248 papers receiving 7.8k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Daniel J. George United States | 48 | 4.7k | 3.3k | 2.9k | 1.9k | 913 | 255 | 8.0k | ||
| Eva Corey United States | 50 | 3.9k 0.8× | 3.8k 1.1× | 3.3k 1.1× | 1.8k 0.9× | 1.1k 1.2× | 194 | 7.9k | ||
| Scott North Canada | 39 | 5.5k 1.2× | 2.6k 0.8× | 2.8k 1.0× | 2.2k 1.1× | 1.2k 1.4× | 193 | 7.6k | ||
| Daniel J. George United States | 37 | 5.4k 1.2× | 3.4k 1.0× | 3.1k 1.1× | 2.7k 1.4× | 751 0.8× | 255 | 7.9k | ||
| Elisabeth I. Heath United States | 48 | 3.2k 0.7× | 3.2k 1.0× | 3.1k 1.1× | 1.5k 0.8× | 727 0.8× | 342 | 8.5k | ||
| Neeraj Agarwal United States | 43 | 5.9k 1.3× | 2.6k 0.8× | 4.2k 1.5× | 2.5k 1.3× | 1.3k 1.4× | 437 | 9.4k | ||
| David F. Jarrard United States | 49 | 5.0k 1.1× | 4.0k 1.2× | 2.1k 0.7× | 2.0k 1.0× | 1.3k 1.4× | 207 | 10.0k | ||
| Olivier Rixe France | 44 | 5.7k 1.2× | 5.3k 1.6× | 4.9k 1.7× | 2.8k 1.4× | 627 0.7× | 205 | 11.3k | ||
| Francesco Cognetti Italy | 46 | 2.3k 0.5× | 2.4k 0.7× | 5.0k 1.7× | 1.7k 0.9× | 1.0k 1.1× | 221 | 8.5k | ||
| Anthony M. Joshua Canada | 44 | 3.4k 0.7× | 2.1k 0.6× | 3.9k 1.3× | 1.6k 0.8× | 1.4k 1.5× | 326 | 7.8k | ||
| Patricia Keegan United States | 54 | 3.1k 0.7× | 2.1k 0.6× | 5.0k 1.7× | 1.6k 0.8× | 712 0.8× | 140 | 9.3k |
Countries citing papers authored by Daniel J. George
Since
Specialization
Citations
This map shows the geographic impact of Daniel J. George's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel J. George with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel J. George more than expected).
Fields of papers citing papers by Daniel J. George
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Daniel J. George. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel J. George. The network helps show where Daniel J. George may publish in the future.
Co-authorship network of co-authors of Daniel J. George
This figure shows the co-authorship network connecting the top 25 collaborators of Daniel J. George. A scholar is included among the top collaborators of Daniel J. George based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel J. George. Daniel J. George is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Jin, Chen, David Moon, Hong Zhang, et al.. (2025). Resilience and Vulnerabilities of Tumor Cells under Purine Shortage Stress. Clinical Cancer Research. 31(20). 4345–4360.
2.
Bhavsar, Nrupen A., Michael R. Harrison, Charles D. Scales, et al.. (2024). Design and Rationale of the Outcomes Database to Prospectively Assess the Changing Therapy Landscape in Renal Cell Carcinoma Registry: A Multi-institutional, Prospective Study of Patients with Metastatic Renal Cell Carcinoma. European Urology Open Science. 66. 75–81.
3.
Halabi, Susan, Joseph J. Park, David M. Nanus, et al.. (2024). The Impact of Circulating Tumor Cell HOXB13 RNA Detection in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide. Clinical Cancer Research. 30(6). 1152–1159.
4.
Kaye, Deborah R., Erik Muser, Laura Morrison, et al.. (2024). Real-world economic burden of metastatic castration-resistant prostate cancer before and after first-line therapy initiation. Journal of Medical Economics. 27(1). 201–214.
5.
Bitting, Rhonda L., Yuan Wu, Jason A. Somarelli, et al.. (2023). Transcriptomic Signatures Associated With Outcomes in Recurrent Prostate Cancer Treated With Salvage Radiation, Androgen-Deprivation Therapy, and Enzalutamide: Correlative Analysis of the STREAM Trial. JCO Precision Oncology. 7(7). e2300214–e2300214.
6.
Halabi, Susan, Qian Yang, Daniel J. George, et al.. (2023). PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer. Clinical Cancer Research. 29(10). 1929–1937.
7.
Wilson, Lauren E., Bradford E. Jackson, Lisa P. Spees, et al.. (2022). End-of-Life Care for Patients With Metastatic Renal Cell Carcinoma in the Era of Oral Anticancer Therapy. JCO Oncology Practice. 19(2). e213–e227.
8.
Lim, Emerson A., Johanna C. Bendell, Gerald S. Falchook, et al.. (2022). Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors. Clinical Cancer Research. 28(22). 4871–4884.
9.
Chen, Yu‐Wei, Matthew D. Tucker, Landon C. Brown, et al.. (2022). The Association between a Decrease in On-Treatment Neutrophil-to-Eosinophil Ratio (NER) at Week 6 after Ipilimumab Plus Nivolumab Initiation and Improved Clinical Outcomes in Metastatic Renal Cell Carcinoma. Cancers. 14(15). 3830–3830.
10.
Spees, Lisa P., Stephanie B. Wheeler, Bradford E. Jackson, et al.. (2021). Provider‐ and patient‐level predictors of oral anticancer agent initiation and adherence in patients with metastatic renal cell carcinoma. Cancer Medicine. 10(19). 6653–6665.
11.
Brown, Landon C., Kunal Desai, Wei Wei, et al.. (2021). Clinical outcomes in patients with metastatic renal cell carcinoma and brain metastasis treated with ipilimumab and nivolumab. Journal for ImmunoTherapy of Cancer. 9(9). e003281–e003281.
12.
Vince, Randy, et al.. (2021). Racial disparities in prostate cancer among black men: epidemiology and outcomes. Prostate Cancer and Prostatic Diseases. 25(3). 397–402.
13.
Flaifel, Abdallah, Wanling Xie, David A. Braun, et al.. (2019). PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN. Clinical Cancer Research. 25(20). 6080–6088.
14.
Staehler, Michael, Robert J. Motzer, Daniel J. George, et al.. (2018). Adjuvant sunitinib in patients with high-risk renal cell carcinoma: safety, therapy management, and patient-reported outcomes in the S-TRAC trial. Annals of Oncology. 29(10). 2098–2104.
15.
Choueiri, Toni K., Susan Halabi, Ben L. Sanford, et al.. (2017). Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial. Journal of Clinical Oncology. 35(6). 591–597.
16.
Tang, Xiaohu, Jianli Wu, Chien‐Kuang Cornelia Ding, et al.. (2016). Cystine Deprivation Triggers Programmed Necrosis in VHL-Deficient Renal Cell Carcinomas. Cancer Research. 76(7). 1892–1903.
17.
George, Daniel J., Chadi Nabhan, Todd DeVries, James B. Whitmore, & Leonard G. Gomella. (2015). Survival Outcomes of Sipuleucel-T Phase III Studies: Impact of Control-Arm Cross-Over to Salvage Immunotherapy. Cancer Immunology Research. 3(9). 1063–1069.
18.
Lassen, Michael R., Winfield S. Fisher, Patrick Mouret, et al.. (2012). Semuloparin for prevention of venous thromboembolism after major orthopedic surgery: results from three randomized clinical trials, SAVE‐HIP1, SAVE‐HIP2 and SAVE‐KNEE. Journal of Thrombosis and Haemostasis. 10(5). 822–832.
19.
Ellis, Leigh, Yan Pan, Gordon K. Smyth, et al.. (2008). Histone Deacetylase Inhibitor Panobinostat Induces Clinical Responses with Associated Alterations in Gene Expression Profiles in Cutaneous T-Cell Lymphoma. Clinical Cancer Research. 14(14). 4500–4510.
20.
Febbo, Phillip G., Aaron R. Thorner, Mark A. Rubin, et al.. (2006). Application of Oligonucleotide Microarrays to Assess the Biological Effects of Neoadjuvant Imatinib Mesylate Treatment for Localized Prostate Cancer. Clinical Cancer Research. 12(1). 152–158.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Eva Corey Breakdown of academic impact, for papers by Scott North Breakdown of academic impact, for papers by Daniel J. George Breakdown of academic impact, for papers by Elisabeth I. Heath Breakdown of academic impact, for papers by Neeraj Agarwal Breakdown of academic impact, for papers by David F. Jarrard Breakdown of academic impact, for papers by Olivier Rixe Breakdown of academic impact, for papers by Francesco Cognetti Breakdown of academic impact, for papers by Anthony M. Joshua Breakdown of academic impact, for papers by Patricia Keegan